BTIG lowered the firm's price target on Evolus to $13 from $18 and keeps a Buy rating on the shares. The firm is updating its model to reflect updated 2026 and long-term guidance while noting that rebasing the market size and outlook was an appropriate step following steep declines across the aesthetic injectables category in 2025, the analyst tells investors in a research note.
